Estrella’s EB103 kept early lymphoma remissions intact, but one trial detail still needs explaining
Estrella advances EB103 into STARLIGHT-1 expansion as early lymphoma remissions endure, while trial scale, safety and funding remain key tests.
Pharma & Biotech